Docoh
Loading...

HAE Haemonetics

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following business segments: Plasma, Blood Center and Hospital. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment offers a range of solutions that improve donor collection centers' ability to acquire blood, filter blood and separate blood components. The Hospital segment provides heomostasis management, cell salvage and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Braintree, MA.

Company profile

Ticker
HAE
Exchange
CEO
Christopher Simon
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
42882273

HAE stock data

(
)

Calendar

2 Feb 21
18 Apr 21
3 Apr 22
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Mar 20 Mar 19 Mar 18 Mar 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Haemonetics earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 189M 189M 189M 189M 189M 189M
Cash burn (monthly) 30.06M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 113.6M n/a n/a n/a n/a n/a
Cash remaining 75.4M n/a n/a n/a n/a n/a
Runway (months of cash) 2.5 n/a n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
8 Mar 21 Basil Michelle L Common Stock Sell Dispose S No No 120.07 385 46.23K 15,607
8 Mar 21 Scanlan Jacqueline Common Stock Sell Dispose S No No 120.07 107 12.85K 4,380
4 Feb 21 Goldstein Dan Common Stock Sell Dispose S No No 136.26 238 32.43K 1,511
4 Feb 21 Goldstein Dan Common Stock Sell Dispose S No No 135.72 500 67.86K 1,749
4 Feb 21 Goldstein Dan Common Stock Option exercise Aquire M No No 98.025 500 49.01K 2,249
4 Feb 21 Goldstein Dan Common Stock Sell Dispose S No No 135.88 476 64.68K 1,749
4 Feb 21 Goldstein Dan Common Stock Option exercise Aquire M No No 93.52 476 44.52K 2,225
4 Feb 21 Goldstein Dan Common Stock Sell Dispose S No No 135.84 1,457 197.92K 1,749
4 Feb 21 Goldstein Dan Common Stock Option exercise Aquire M No No 34.21 1,457 49.84K 3,206
4 Feb 21 Goldstein Dan NQSO Common Stock Option exercise Dispose M No No 98.025 500 49.01K 1,503

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

97.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 283 264 +7.2%
Opened positions 54 40 +35.0%
Closed positions 35 57 -38.6%
Increased positions 74 86 -14.0%
Reduced positions 113 105 +7.6%
13F shares
Current Prev Q Change
Total value 5.89B 4.26B +38.4%
Total shares 49.61M 48.79M +1.7%
Total puts 134.9K 100K +34.9%
Total calls 120.5K 157K -23.2%
Total put/call ratio 1.1 0.6 +75.8%
Largest owners
Shares Value Change
Capital Research Global Investors 5.64M $669.48M +16.8%
Vanguard 4.85M $576.21M -0.3%
BLK Blackrock 4.7M $558.2M -3.9%
ATAC Neuberger Berman 2.83M $335.64M -1.9%
FMR 2.48M $294.93M +10.2%
BEN Franklin Resources 1.8M $213.29M +4.2%
Renaissance Technologies 1.58M $187.17M -18.5%
Wellington Management 1.36M $162.01M +8.0%
STT State Street 1.22M $145.02M -0.1%
WFC Wells Fargo & Co. 1.22M $144.4M +17.4%
Largest transactions
Shares Bought/sold Change
Point72 Asset Management 280.43K -1.39M -83.2%
London Co Of Virginia 940.22K +940.22K NEW
Capital Research Global Investors 5.64M +812.22K +16.8%
HealthCor Management 566.37K +566.37K NEW
Norges Bank 503.37K +503.37K NEW
Renaissance Technologies 1.58M -357.99K -18.5%
Capital World Investors 1.18M +346.7K +41.5%
Westfield Capital Management 532.64K -309.77K -36.8%
Carmignac Gestion 305.55K +305.55K NEW
Polar Capital 289.09K +289.09K NEW

Financial report summary

?
Competition
TerumoExactus
Risks
  • The ongoing COVID-19 pandemic, or outbreaks of communicable diseases, could have a material adverse impact on our business, financial condition, cash flows and results of operations, which may be heightened if the pandemic and various government responses to it continue for an extended period of time.
  • If our business strategy does not yield the expected results or we fail to implement the necessary changes to our operations, we could see material adverse effects on our business, financial condition or results of operations.
  • Material reductions in purchasing from or loss of a significant customer could adversely affect our business.
  • Defects or quality issues associated with our products could adversely affect the results of operations.
  • If we are unable to successfully convert customers to our NexSys platform, meet customer placement demands or negotiate competitive pricing, we may not realize the intended benefits of our investment.
  • We are increasingly dependent on information technology systems and subject to privacy and security laws and a cyber-attack or other breach of these systems could have a material adverse effect on our business, financial condition or results of operations.
  • A significant portion of our revenue derives from the sale of blood collection supplies. Declines in the number of blood collection procedures have adversely impacted our business and future declines may have an adverse effect on our business, financial condition and results of operations.
  • Consolidation of healthcare providers and blood collectors has increased demand for price concessions and caused the exclusion of suppliers from significant market segments, which could have an adverse effect on our business, financial condition and results of operations.
  • An interruption in our ability to manufacture our products, obtain key components or raw materials, or the failure of a sole source supplier may adversely affect our business.
  • Plastics are the principal component of our disposables, which are the main source of our revenues. Any change in the price, composition or availability of the plastics or resins we purchase could adversely affect our business.
  • If we are unable to successfully expand our product lines through internal research and development, our business may be materially and adversely affected.
  • We may not realize the benefits we expect from our Operational Excellence Program.
  • If our business development activities are unsuccessful, we may not realize the intended benefits.
  • As a medical device manufacturer we operate in a highly regulated industry, and non-compliance with applicable laws or regulations could adversely affect our financial condition and results of operations.
  • If we or our suppliers fail to comply with ongoing regulatory requirements, our products could be subject to restrictions or withdrawal from the market.
  • Our inability to obtain, or any delay in obtaining, any necessary U.S. or foreign regulatory clearances or approvals for our newly developed products or product enhancements could harm our business and prospects.
  • Our relationships with customers and third-party payers are subject to applicable anti-kickback, fraud and abuse, transparency and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion, contractual damages, reputational harm and diminished profits and future earnings.
  • As a substantial amount of our revenue comes from outside the U.S., we are subject to geopolitical events, economic volatility, violations of anti-corruption laws, export and import restrictions and tariffs, decisions by local regulatory authorities and the laws and medical practices in foreign jurisdictions.
  • We sell our products in certain emerging economies which exposes us to less mature regulatory systems, more volatile markets for our products and greater credit risks. A loss of funding for our products or changes to the regulatory regime could lead to lost revenue or account receivables.
  • In many of the international markets in which we do business, including certain parts of Europe, South America, the Middle East and Asia, our employees, agents or distributors offer to sell our products in response to public tenders issued by various governmental agencies.
  • Our success depends on our ability to attract and retain key personnel needed to successfully operate the business.
  • We operate in an industry susceptible to significant product liability claims. Product liability claims could damage our reputation and impair our ability to market our products or obtain professional or product liability insurance, or increase the cost of such insurance.
  • If we are unable to meet our debt obligations or experience a disruption in our cash flows, it could have an adverse effect on our financial condition, results of operations or cost of borrowing.
  • Our operations and plans for future growth may require additional capital that may not be available to us, or only available to us on unfavorable terms.
  • We are exposed to fluctuations in currency exchange rates, which could adversely affect our cash flows and results of operations.
  • Our effective tax rate may fluctuate and we may incur obligations in tax jurisdictions in excess of amounts that have been accrued.
  • Changes in tax laws or exposure to additional income tax liabilities could have a material impact on our financial condition, results of operations and/or liquidity.
  • Our share price has been volatile and may fluctuate, and accordingly, the value of an investment in our common stock may also fluctuate.
  • There is a risk that our intellectual property may be subject to misappropriation in some countries.
  • Pending and future intellectual property litigation could be costly and disruptive to us.
  • Our products may be determined to infringe another party's patent, which could lead to financial losses or adversely affect our ability to market our products.
Management Discussion
  • (1) Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency. See “Management's Use of Non-GAAP Measures.”
  • (1) Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency. See “Management's Use of Non-GAAP Measures.”
  • Our principal operations are in the U.S, Europe, Japan and other parts of Asia. Our products are marketed in approximately 85 countries around the world through a combination of our direct sales force, independent distributors and agents. Our revenue generated outside the U.S. was 38.6% and 40.7%, respectively, of total net revenues during the three and nine months ended December 26, 2020, as compared with 35.4% and 35.3%, respectively, during the three and nine months ended December 28, 2019. International sales are generally conducted in local currencies, primarily Japanese Yen, Euro, Chinese Yuan and Australian Dollars. Our results of operations are impacted by changes in foreign exchange rates, particularly in the value of the Yen, Euro and Australian Dollar relative to the U.S. Dollar. We have placed foreign currency hedges to mitigate our exposure to foreign currency fluctuations.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: ablation, arterial, Attorney, augment, autotransfusion, California, cardiac, Cardiva, Clara, closure, Commission, cooperating, demonstrated, developmental, distributor, District, electrophysiology, femoral, greater, growing, hand, headquarter, HemoAssay, inorganic, inquiry, interventional, Merger, MVP, penetration, peripheral, prioritize, Santa, Science, SEC, subpoena, Suzhou, temporary, VASCADE, vascular, vessel
Removed: capacity, CSL, occurred

Patents

GRANT
Utility
Detection and classification of an anticoagulant using a clotting assay
23 Mar 21
In some embodiments, the invention provides methods for detecting and/or classifying an anticoagulant at a therapeutically relevant amount or higher in a patient, including subjecting a sample of a control blood component (known not to contain the anticoagulant) to a clotting assay in the presence of a Factor Xa reagent to obtain a control clotting measurement; and subjecting a sample of a blood component from a patient suspected of having the anticoagulant to the clotting assay in the presence of the Factor Xa reagent to obtain a patient clotting measurement, wherein the patient clotting measurement sample greater than the control clotting measurement indicates the presence of the anticoagulant at a therapeutically relevant amount or higher in the patient.
GRANT
Utility
Peristaltic pump with controlled stop
16 Mar 21
A peristaltic pump includes a rotor and first and second rollers mounted on the rotor.
GRANT
Utility
Diagnostic kit for viscoelastic analysis and uses and methods thereof
2 Mar 21
A diagnostic kit for viscoelastic analysis of a sample includes a pipette tip containing constituent (A) and a measurement cup containing constituent (B), wherein the constituents (A) and (B) are adapted to form a diagnostic composition upon combination, wherein the diagnostic composition includes an activator of coagulation and a calcium salt.
GRANT
Utility
Methodologies and reagents for detecting fibrinolysis and hyperfibrinolysis
2 Mar 21
In some embodiments, the invention provides a container adapted for detecting hyperfibrinolysis or fibrinolysis in a blood sample using viscoelastic analysis comprising an interior having a coating comprises an inhibitor of fibrinolysis.
APP
Utility
Continuous Flow Separation Chamber
6 Jan 21
A continuous flow centrifuge bowl includes a rotatable outer body, and a top and bottom core that are rotatable with the outer body.